SkinCancer360

Checkpoint Therapeutics Receives Approval for PD-L1 Therapy
Featured image for “Checkpoint Therapeutics Receives Approval for PD-L1 Therapy”

Checkpoint Therapeutics Receives Approval for PD-L1 Therapy

December 16, 2024
The approval of cosibelimab-ipdl provides an option for patients with cutaneous squamous cell carcinoma December 13, 2024 (Sacramento, California) The…
[wpb_childpages]

Recent Posts

Featured image for “Wide Local Excision vs. Mohs Surgery: A Dermatologist Explains”
Apr. 23, 2025

Wide Local Excision vs. Mohs Surgery: A Dermatologist Explains

Featured image for “Skin Cancer Risk Persists for 30 Years after Blood Cancer Diagnosis”
Mar. 31, 2025

Skin Cancer Risk Persists for 30 Years after Blood Cancer Diagnosis

Featured image for “A Mohs Surgeon Explains the Procedure”
Feb. 25, 2025

A Mohs Surgeon Explains the Procedure

Featured image for “Checkpoint Therapeutics Receives Approval for PD-L1 Therapy”
Dec. 16, 2024

Checkpoint Therapeutics Receives Approval for PD-L1 Therapy

Featured image for “Active Military Service Veterans are at Risk for Skin Cancers”
Dec. 03, 2024

Active Military Service Veterans are at Risk for Skin Cancers

Post Categories